Abstract 2077P
Background
To investigate the efficacy of Superoxide Dismutase (SOD, 70 UI), Palmitoyethanolamide (PEA, 300 mg) Alpha Lipoic Acid (ALA, 300 mg),vitamins B6 (1.5 mg), B1 (1.1 mg), B12(2.5 mcg), E (7.5 mg), Nicotinamide (9 mg) and minerals (Mg 30 mg, Zn 2,5 mg) in one tablet in managing neuropathic pain due to cancer chemotherapy.
Methods
In this pilot study, 67 age-matched patients with cancer (41 men) and a mean age of 65.4 years were randomly assigned, either to receive the combination of ten elements (2 tablets/24h) in the active A group, (n=33), or the placebo B (n=34) for six months. Nerve function was assessed by DPN Check [sural nerve conduction velocity (SNCV) and amplitude (SNAP)]. Sudomotor function was evaluated with SUDOSCAN, which measures electRochemical skin conductance in hands and feet (ESCH and ESCF). We used Pain questionnaires: Pain Detect (PD), Neuropathic Pain Symptom Inventory (NPSI), and Visual Analog Scale (VAS) for the estimation of neuropathic pain, also. All patients received Taxanes and platinum analogs as cancer chemotherapy.
Results
At follow-up, measurements from SNCV, SNAP, ESCH and ESCF did not change significantly in both groups. In A group PD baseline vs. final (9.57±7.0 vs. 6.78±4.16, p=0.003), NPSI (28.51±21.26 vs. 19.87±12.6, p<0.001) and VAS (27.78±22.40 vs 21.48±17.79, p=0.003) improved significantly during follow up. In group B PD (7.03±5.19 vs. 9.71±6.61 p<0.001), NPSI (23.50±18.99 vs. 36.25±22.15, p<0.001), and VAS (25.03±23.83 vs 38.75±26.60 p<0.001) deteriorated. No side effects detected.
Conclusions
The combination of the ten elements as supplement in one tablet for six months at a daily dose of two pills in patients improved neuropathic pain due to cancer chemotherapy.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2055P - Multidisciplinary Tumor-ICU Board: Enhancing care for critically Ill patients with solid tumors in the ICU
Presenter: Francisco Javier Ros Montana
Session: Poster session 06
2056P - Hospitalization, reconsultations and mortality in the field of oncological emergencies: Who is at higher risk?
Presenter: Eugenia María Martínez Madrid
Session: Poster session 06
2057P - Prevalence of frailty in long-term prostate cancer survivors after radical prostatectomy and its association with quality of life and emotional health
Presenter: Valentin Meissner
Session: Poster session 06
2058P - Reducing waste to improve sustainability and affordability of cancer treatment: Redispensing unused oral anticancer drugs
Presenter: Lisa-Marie Smale
Session: Poster session 06
2059P - The impact of a dental oncology clinic for patients (pts) prescribed bone-modifying agents (BMA) in a cancer centre
Presenter: Harriet Byrne
Session: Poster session 06
2060P - Prevalence and predictor of poor mental adjustment to cancer before lung cancer surgery
Presenter: Junhee Park
Session: Poster session 06
2061P - Network analysis of comprehensive concerns in patients with cancer: Differences between the sexes
Presenter: Kazumasa Yamamoto
Session: Poster session 06
2062P - The psychological distress (PsyD) evaluation in pancreatic cancer (PC) patients (pts): A mono-institutional analysis
Presenter: Maria Bensi
Session: Poster session 06
2063P - Lifestyle changes as cancer treatment: It is time to get specific with our patients
Presenter: Ana Isabel Martin Quesada
Session: Poster session 06
2064P - Hospitalisation of patients with cancer: Identifying points for improvement in patient care in a university hospital in Spain
Presenter: Silvia Roa
Session: Poster session 06